Establishment of the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute

- Researchers discover how to make leukemic cells differentiate into normally behaving cells utilizing several techniques, including activating vitamin D compounds.
- Investigators identify a protein, EMP-1, that is present in tumors of non-small cell lung cancer patients who do not respond to standard treatment.

In the first study to identify weight as an independent factor in ovarian cancer, researchers show that obesity affects survival rates, shortens the length of time to recurrence of the disease, and leads to earlier death from the cancer.

A dedicated sarcoma program opens, offering patients access to an array of specialists with experience in diagnosing and treating this rare form of cancer.

A new technology becomes available to provide highly focused, image-guided radiotherapy and radiosurgery, ideal for treating tumors near the spinal cord, liver and previously inoperable lung lesions.

The Blood and Marrow Transplant Program receives national attention for its creation and design of bloodless bone marrow transplants for Jehovah’s Witness patients, a group that does not accept blood transfusions.

The Clinical Research Office opens to facilitate a wide range of research services to clinical investigators and has since expanded to nearly 60 employees.

To help researchers understand the biological interplay among hormones, diet, genetics and metabolism in cancer, the Cancer Screening and Prevention program is established.

- Clinical trial participation grows 60 percent over two years. Research for Her™, an online registry, launches to link women with or without cancer to research opportunities with an ultimate goal of improving the well-being of all women.
- The High-Risk Breast Cancer Program is built to regularly monitor high-risk women with a family history of breast cancer.
- The number of faculty physicians representing all areas of oncology grows 340 percent in five years.

To speed the progress of promising new treatments and encourage translational research to accelerate drug development, the Phase I Unit for Experimental Therapeutics opens its clinic doors to patients.

Next generation sequencing is now offered to patients, building a broader range of treatment options based on the individual makeup of their tumors.

In honor of past, present and future clinical trial participants, a video highlights the value and importance of participating in clinical research.

Research for Her™ website

Since 2004, the Samuel Oschin Comprehensive Cancer Institute has helped fight cancer in the Los Angeles community and around the globe. As we mark the 10th anniversary of the institute, we look back at some of the most significant contributions and advancements made within its walls – toward the prevention, diagnosis and treatment of cancer.